QPPV.COM KNOWLEDGE ASSESSMENT

Sarilumab Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Sarilumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which information would be most valuable when following up a serious or opportunistic infection during Sarilumab treatment?

Only the patient's age and the date of the next scheduled dose Site, organism, cultures, imaging, antimicrobial treatment, immune status and outcome Only whether the event was reported by a healthcare professional The patient's preferred injection device without clinical information

Question 2 of 10 Which follow-up approach is most appropriate for a suspected lack of Sarilumab effect or disease rebound?

Ask only whether the patient reported feeling worse Review schedule, adherence, interruptions, disease measurements, treatment changes and switching Assume that any worsening proves pharmacological failure Exclude the case because lack of effect is not a safety-related topic

Question 3 of 10 Which combination of factors represents the three interacting layers of Sarilumab safety assessment?

Marketing status, sales volume and product price Direct pharmacology, host susceptibility and treatment environment Batch number, packaging colour and prescriber specialty Disease name, laboratory reference range and report source only

Question 4 of 10 A patient develops neutropenia after starting Sarilumab. Which approach is most scientifically appropriate?

Assume causality solely because neutropenia is biologically plausible Assess baseline counts, serial trends, symptoms, disease activity, concomitant medicines and clinical consequences Exclude the event from review because it is a laboratory finding Classify it as product quality failure without examining the patient

Question 5 of 10 A patient develops an event several weeks after Sarilumab is interrupted. Which conclusion is most appropriate?

The event cannot be related because treatment had already stopped The event should be assessed with attention to possible persistence of biological effect, delayed onset, alternative causes and the full chronology The event should automatically be classified as a new unrelated illness Interruption is definitive evidence of complete dechallenge

Question 6 of 10 Which governance evidence would best demonstrate that an organisation's Sarilumab pharmacovigilance process is effective rather than merely documented?

A procedure exists, but no records show how cases were followed up or assessed Records show targeted follow-up, medical review, indication-specific analysis, reconciliation and documented escalation decisions A product brochure is stored in the quality system All cases are processed using one undifferentiated exposure field

Question 7 of 10 What is the principal benefit of recording product presentation, batch, storage and preparation details in a suspected quality-related case?

It allows the case to be closed without medical review It supports traceability, investigation of clusters and reconciliation with quality and distribution records It proves that the adverse event was caused by the product It replaces the need to document dose and administration date

Question 8 of 10 Which case narrative best supports a medically meaningful causality assessment?

The event occurred after treatment, so Sarilumab was considered causal The narrative records exposure dates, phenotype, objective findings, competing causes, management, outcome and treatment changes The narrative uses the term 'immune-mediated' without supporting clinical evidence The narrative lists the event term but omits disease activity and concomitant medicines

Question 9 of 10 A report describes fever in a patient receiving Sarilumab. What is the most appropriate initial pharmacovigilance interpretation?

Fever should automatically be attributed to IL-6 receptor blockade Fever should be disregarded because it is a nonspecific symptom The reviewer should evaluate infection, disease activity, administration reaction and other plausible causes using chronology and objective findings The report should be coded only as treatment failure

Question 10 of 10 Which statement best explains why the authorised treatment context should be recorded in a Sarilumab case?

It is needed only for commercial reporting and has no medical relevance It helps distinguish disease-related morbidity, treatment intent and background risk from treatment-related effects It replaces the need to record concomitant medicines It ensures that every event is considered expected

QPPV.com

Sarilumab Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings